Clinical evidence-guided network pharmacology analysis reveals a critical contribution of β1-adrenoreceptor upregulation to bradycardia alleviation by Shenxian-Shengmai

BACKGROUND: Shenxian-Shengmai (SXSM) Oral Liquid is a CFDA-approved patent Chinese Herbal medicine, which has been clinically used for the treatment of bradycardia. However, its active components and action mechanism remain to be established. The present study aimed to evaluate the efficacy of SXSM...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Jiaming, Wang, Taiyi, Yao, Xi, Xie, Weiwei, Shi, Xianru, He, Shuang, Zhao, Tao, Wang, Chunhua, Zhu, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902583/
https://www.ncbi.nlm.nih.gov/pubmed/31822281
http://dx.doi.org/10.1186/s12906-019-2769-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902583/
https://www.ncbi.nlm.nih.gov/pubmed/31822281
http://dx.doi.org/10.1186/s12906-019-2769-0

Ejemplares similares